Robert “Bob” Tepper is a co-founder of Third Rock Ventures and a distinguished scientist with more than 30 years of experience building and operating leading R&D organizations in the biotech industry. Bob focuses on the formation, development and scientific strategy of Third Rock’s portfolio companies, as well as identifying and evaluating new investments. He has also assumed leadership roles in a number of Third Rock’s portfolio companies, previously serving as interim chief scientific officer of Constellation Pharmaceuticals, Jounce Therapeutics and Neon Therapeutics. Bob currently serves as a board member of Neon Therapeutics, Allena Pharmaceuticals, Constellation Pharmaceuticals, Jounce Therapeutics and Kala Pharmaceuticals.
Prior to joining Third Rock, Bob was president of R&D at Millennium Pharmaceuticals and was vital in its expansion from a drug discovery company to a fully integrated biopharmaceutical company. Earlier, Bob co-founded Cell Genesys/Abgenix.
Bob holds an A.B. in biochemistry from Princeton University and received his M.D. from Harvard Medical School. Bob currently serves as an adjunct faculty member at Harvard Medical School and Massachusetts General Hospital and is an advisory board member of several leading health care institutions, including the Partners HealthCare Center for Personalized Genetic Medicine, Harvard Medical School and Tufts Medical School. Bob is on the Board of Overseers at Tufts University. He also serves on the Council of the National Center for the Advancement of Translational Sciences at the National Institutes of Health.